Story

Hims & Hers Stock Slides on Wider-Than-Expected Q2 Loss

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Hims & Hers Stock Slides on Wider-Than-Expected Q2 Loss
Text size
Background

Shares of Hims & Hers Health Inc. (NYSE: HIMS) declined more than 7% in pre-market trading after the telehealth company reported a second-quarter loss that was substantially wider than Wall Street forecasts. The significant earnings miss overshadowed strong revenue growth and a raised annual outlook, sparking investor concerns over the company's path to sustained profitability.

Earnings Report Disappoints

In its Q2 2026 results released after Monday's close, Hims & Hers disclosed a mixed performance that ultimately failed to reassure investors. While revenue impressed, the bottom line fell far short of expectations.

Key figures from the report include:

  • Loss Per Share: A net loss of $0.37, which was significantly larger than the consensus analyst forecast for a loss of just $0.05.
  • Revenue: Approximately $753 million, representing a 38% increase year-over-year and beating consensus estimates by nearly 9%.
  • Q3 Guidance: The company's forecast for third-quarter adjusted EBITDA came in below Wall Street's expectations.

The combination of a steep earnings miss and a cautious near-term profitability outlook appeared to be the primary drivers of the negative investor reaction.

Margin Pressure and Cash Flow Concerns

Sample IUX Markets – In-articleAd

The wider-than-expected loss was primarily attributed to significant pressure on the company's gross margins, which fell to approximately 64%. According to the report, this compression stems from the company's strategic shift away from compounded GLP-1 medications toward more expensive branded weight-loss drugs. The transition resulted in $4.6 million in restructuring charges during the quarter.

Adding to the concerns, free cash flow remained deeply negative at around -$68 million. This figure highlights the cash burn associated with the company's current strategy, further worrying investors focused on the company's financial stability.

Outlook and Market Context

Despite the quarterly loss, management expressed confidence in its top-line growth by raising its full-year 2026 revenue guidance to a new range of $3.1 billion to $3.3 billion. However, this positive development was not enough to offset the immediate concerns about profitability.

An existing Federal Trade Commission (FTC) lawsuit, which alleges the company shared sensitive user health data with third-party advertisers, also remains a legal overhang for the stock. With the broader U.S. stock market trading nearly flat, the sharp drop in Hims & Hers shares was driven almost entirely by these company-specific factors.

Read next

More on Stocks
Back to latest news

LATEST